Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H19N4O6.Na |
Molecular Weight | 398.3457 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)[N-]C(=O)C3=N2
InChI
InChIKey=YXJHJCDOUFKMBG-BMZHGHOISA-M
InChI=1S/C17H20N4O6.Na/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15;/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27);/q;+1/p-1/t11-,12+,14-;/m0./s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H19N4O6 |
Molecular Weight | 375.356 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22406738
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22406738
Riboflavin (vitamin B2) is part of the vitamin B group. Riboflavin 5’-phosphate is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. FAD and riboflavin phosphate in foods are hydrolyzed in the intestinal lumen by nucleotide diphosphatase and a variety of nonspecific phosphatases to yield free riboflavin, which is absorbed in the upper small intestines by a sodium-dependent saturable mechanism. Riboflavin has been used in several clinical and therapeutic situations. For over 30 years, riboflavin supplements have been used as part of the phototherapy treatment of neonatal jaundice. Corneal ectasia is a progressive thinning of the cornea; the most common form of this condition is keratoconus. Collagen cross-linking is a non-surgical treatment intended to slow progression of corneal ectasia by strengthening corneal tissue. The standard protocol calls for application directly to the eye of a 0.1% riboflavin solution for 30 minutes followed by 30 minutes of ultraviolet-A irradiation with a wavelength of 370 nm and power of 3 mW/cm2. Under the conditions used for corneal collagen cross-linking, riboflavin 5‘-phosphate functions as a photo enhancer and generates singlet oxygen which is responsible for the cross-linking.
Originator
Sources: Journal of Biological Chemistry (1928), 79, 733-8.iez8K9UZvDozY4ZRMmHj4&hl=ru&sa=X&ved=0ahUKEwiJ1reL0b_PAhWJVBQKHbdGBvEQ6AEIQjAF#v=onepage&q=Vitamin%20B2%20was%20discovered%20in%201920s&f=false
Curator's Comment: https://books.google.ru/books?id=b9ahvNjPFO8C&pg=PA63&lpg=PA63&dq=Vitamin+B2+was+discovered+in+1920s&source=bl&ots=KeZDSvz8CS&sig=gvCH_-
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PHOTREXA Approved UsePHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of 1.1 Progressive keratoconus 1.2 Corneal ectasia following refractive surgery. Launch Date2016 |
|||
Primary | PHOTREXA Approved UsePHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of 1.1 Progressive keratoconus 1.2 Corneal ectasia following refractive surgery. Launch Date2016 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
217.72 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8604671 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
674.2 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8604671 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
66 min |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of vitamins on hepatic nuclear binding of L-tryptophan. | 2001 |
|
The stressed synovium. | 2001 |
|
Serum levels assessment of vitamin A, E, C, B2 and carotenoids in malnourished and non-malnourished hospitalized elderly patients. | 2001 Apr |
|
Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening. | 2001 Apr 17 |
|
Domain structure of riboflavin synthase. | 2001 Aug |
|
Nutritional evaluation of some processed catering foods. | 2001 Jan |
|
Protein-based chiral stationary phases for high-performance liquid chromatography enantioseparations. | 2001 Jan 12 |
|
Novel pH-sensitive citrate cross-linked chitosan film for drug controlled release. | 2001 Jan 5 |
|
Spatially focused deposition of capillary electrophoresis effluent onto surface-enhanced Raman-active substrates for off-column spectroscopy. | 2001 Jul |
|
Nutritional composition of uncommon foods and their role in meeting micronutrient needs. | 2001 Jul |
|
Riboflavin uptake in human trophoblast-derived BeWo cell monolayers: cellular translocation and regulatory mechanisms. | 2001 Jul |
|
Considerations in planning vegan diets: children. | 2001 Jun |
|
[Energy and nutrient intake in compulsory high school students]. | 2001 Jun |
|
Biosynthesis of riboflavin: studies on the mechanism of GTP cyclohydrolase II. | 2001 Jun 22 |
|
Relationships between dietary intake and cognitive function level in Korean elderly people. | 2001 Mar |
|
Limiting light-induced lipid peroxidation and vitamin loss in infant parenteral nutrition by adding multivitamin preparations to Intralipid. | 2001 Mar |
|
Steady-state and time-resolved spectroscopy of F420 extracted from methanogen cells and its utility as a marker for fecal contamination. | 2001 Mar |
|
[Effect of coenzyme Q10 in patients with kidney diseases]. | 2001 May 24 |
|
Nutritional assessment in various stages of liver cirrhosis. | 2001 Sep |
|
Crystallization and preliminary crystallographic analysis of the recombinant N-terminal domain of riboflavin synthase. | 2001 Sep |
|
Stoichiometric growth model for riboflavin-producing Bacillus subtilis. | 2001 Sep |
|
A Plackett-Burnam screening design directs the efficient formulation of multicomponent DRV liposomes. | 2001 Sep |
|
Riboflavin carrier protein: a serum and tissue marker for breast carcinoma. | 2001 Sep 20 |
|
The pH-dependent role of superoxide in riboflavin-catalyzed photooxidation of 8-oxo-7,8-dihydroguanosine. | 2001 Sep 6 |
Patents
Sample Use Guides
instill 1 drop topically on the eye every 2 minutes for 30 minutes. After 30 minutes, examine the eye under slit lamp for presence of a yellow
flare in the anterior chamber. If flare is not detected, instill 1 drop every 2 minutes for an additional 2 to 3 drops and recheck for yellow flare.
Once flare is observed, perform ultrasound pachymetry. If corneal
thickness is less than 400 microns, instill 2 drops every 5 to 10 seconds until the corneal thickness increases to at least 400 microns.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27463630
Corneal stromal cells were covered with collagen (200 µL or 500 µL) and 0.1% riboflavin, and then exposed to ultraviolet light at 370 nm for 30 minutes
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:53 GMT 2023
by
admin
on
Fri Dec 15 15:22:53 GMT 2023
|
Record UNII |
04SRR95RP8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002842
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
100000176159
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
2109051
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
176853
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
7681-29-0
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
04SRR95RP8
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
04SRR95RP8
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
DTXSID00998130
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY | |||
|
76964699
Created by
admin on Fri Dec 15 15:22:54 GMT 2023 , Edited by admin on Fri Dec 15 15:22:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |